SCHEMBL796093

SCHEMBL796093

CN(CCO)S(C)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4374314 0.84 MEN1 (0.43)
SCHEMBL15384964 0.80 MEN1 (0.36)
SCHEMBL24177243 0.77 TSHR (0.42)
SCHEMBL7198490 0.76 MAPT (0.41)
SCHEMBL10317295 0.76
SCHEMBL15839416 0.75 KMT2A (0.36)
SCHEMBL48410 0.74 MEN1 (0.42)
SCHEMBL5176138 0.74 MAPT (0.38)
SCHEMBL4886131 0.74
SCHEMBL9682044 0.74 SMN1; SMN2 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2380878-B1 CYCLIC COMPOUND HAVING HETERO ATOM DAIICHI SANKYO CO LTD (JP) 2013-08-14 EP claimed
US-20110269746-A1 CYCLIC COMPOUND HAVING HETERO ATOM DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-11-03 US claimed
EP-2380878-A1 CYCLIC COMPOUND HAVING HETERO ATOM Daiichi Sankyo Company, Limited (JP) 2011-10-26 EP claimed
CN-120152972-A Thiadiazole derivative, composition and application thereof 北京丹擎医药科技有限公司 2025-06-13 CN disclosed
WO-2024099336-A1 THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2024-05-16 WO disclosed
US-20230355626-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2023-11-09 US disclosed
EP-4114834-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2023-01-11 EP disclosed
CN-115551858-A Inhibitors of human immunodeficiency virus replication VIIV保健英国第五有限公司 2022-12-30 CN disclosed
WO-2021176366-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-09-10 WO disclosed
US-11028093-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-06-08 US disclosed
WO-2020227097-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-11-12 WO disclosed
WO-2002016348-A1 ANTIANGIOGENIC BICYCLIC DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 WO disclosed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 WO disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 WO disclosed
WO-2002012227-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed
EP-0215733-B1 PYRIDYLOXYPHENOXYPROPIONIC ACID DERIVATIVES SANDOZ AG (CH) 1989-06-21 EP disclosed
EP-0215733-A1 Pyridyloxyphenoxypropionic acid derivatives SANDOZ AG (CH) 1987-03-25 EP disclosed
US-4629497-A Certain 1-(N-methylsulfonamido)-prop-2-yl 2-/4-(pyrid-2-yloxy)phenoxy/-propionate derivatives and their use for increasing recoverable sugar contained in sugar cane SANDOZ LTD. (CH) 1986-12-16 US disclosed